Loading…
Editorial: Disease-on-a-chip: from point-of-care to personalized medicine
[Excerpt] Introduction Miniaturization has played a pivotal role in driving innovation in microfluidic devices, particularly in their application across advanced technologies, such as Lab-on-chip platforms, Point-of-care systems, Organ-, Body- and Disease-on-a-chip technology. The personalized natur...
Saved in:
Published in: | Frontiers in pharmacology 2023-12, Vol.14, p.1344379-1344379 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 1344379 |
container_issue | |
container_start_page | 1344379 |
container_title | Frontiers in pharmacology |
container_volume | 14 |
creator | Cruz, Andrea Fernandes, Elisabete Rodrigues, Raquel Oliveira Catarino, Susana Oliveira Pinho, Diana |
description | [Excerpt] Introduction Miniaturization has played a pivotal role in driving innovation in microfluidic devices, particularly in their application across advanced technologies, such as Lab-on-chip platforms, Point-of-care systems, Organ-, Body- and Disease-on-a-chip technology. The personalized nature inherent in these systems, coupled with physiologically relevant readouts, opens novel avenues for individualized disease diagnostics, Figure 1. Additionally, they offer personalized strategies for assessing treatment efficacy and safety. Furthermore, the advancement in micro- and nano-microfluidic fabrication allows parallel analysis of large samples sets and the evaluation of different parameters such as biological molecules, cells or drugs.[...]
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The authors declare financial support: AC and EF are supported by the Lifesaver project funded by the European Union´s Horizon 2020 Research and Innovation Programme under the Grant agreement number 101036702; DP, SC, and RR thanks to Foundation for Science and Technology (FCT) for the contract funding provided through 2021.00027.CEECIND, 2020.00215.CEECIND and 2020.03975.CEECIND, respectively. |
doi_str_mv | 10.3389/fphar.2023.1344379 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_1977fed94f6a4fa8a94b973d41d90cc1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_1977fed94f6a4fa8a94b973d41d90cc1</doaj_id><sourcerecordid>2906178387</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3609-e519417238b6435a09c40d495af19985b6ed6418b317eca89910de3d42d5212b3</originalsourceid><addsrcrecordid>eNpVkU1P3DAQhq2qVUGUP8ChyrGXbP0Vx8OlqigtKyH1Us7WxJ6wRtk4tbNI9Nc3sAsCX2zZ7zye0cPYmeArpSx87acN5pXkUq2E0lq18I4dC2NUDVbI96_OR-y0lDu-LAWgjP7IjpQV2mgjj9n6MsQ55YjDefUjFsJCdRprrP0mTudVn9O2mlIc5zr1tcdM1ZyqiXJJIw7xH4VqSyH6ONIn9qHHodDpYT9hNz8v_1xc1de_f60vvl_XXhkONTUCtGilsp3RqkEOXvOgocFeANimMxSMFrZToiWPFkDwQCpoGRopZKdO2HrPDQnv3JTjFvODSxjd00XKtw7zHP1ATkDb9hRA9wZ1jxZBd9AuLBGAey8W1rc9a9p1yxyexjnj8Ab69mWMG3eb7p3grQYJaiF8ORBy-rujMrttLJ6GAUdKu-IkcCNaq2y7ROU-6nMqJVP_8o_g7tGpe3LqHp26g9Ol6PPrDl9Kng0ugWofyB5xcpnuY5mxOGGldNaaRqn_oeinfg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2906178387</pqid></control><display><type>article</type><title>Editorial: Disease-on-a-chip: from point-of-care to personalized medicine</title><source>PubMed Central</source><creator>Cruz, Andrea ; Fernandes, Elisabete ; Rodrigues, Raquel Oliveira ; Catarino, Susana Oliveira ; Pinho, Diana</creator><creatorcontrib>Cruz, Andrea ; Fernandes, Elisabete ; Rodrigues, Raquel Oliveira ; Catarino, Susana Oliveira ; Pinho, Diana</creatorcontrib><description>[Excerpt] Introduction Miniaturization has played a pivotal role in driving innovation in microfluidic devices, particularly in their application across advanced technologies, such as Lab-on-chip platforms, Point-of-care systems, Organ-, Body- and Disease-on-a-chip technology. The personalized nature inherent in these systems, coupled with physiologically relevant readouts, opens novel avenues for individualized disease diagnostics, Figure 1. Additionally, they offer personalized strategies for assessing treatment efficacy and safety. Furthermore, the advancement in micro- and nano-microfluidic fabrication allows parallel analysis of large samples sets and the evaluation of different parameters such as biological molecules, cells or drugs.[...]
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The authors declare financial support: AC and EF are supported by the Lifesaver project funded by the European Union´s Horizon 2020 Research and Innovation Programme under the Grant agreement number 101036702; DP, SC, and RR thanks to Foundation for Science and Technology (FCT) for the contract funding provided through 2021.00027.CEECIND, 2020.00215.CEECIND and 2020.03975.CEECIND, respectively.</description><identifier>ISSN: 1663-9812</identifier><identifier>EISSN: 1663-9812</identifier><identifier>DOI: 10.3389/fphar.2023.1344379</identifier><identifier>PMID: 38146462</identifier><language>eng</language><publisher>Switzerland: Frontiers Media</publisher><subject>Biotecnologia Médica ; Ciências Médicas ; Detection systems ; Digital pills ; drug-device ; lab-on-chip ; Microfluidic devices ; Miniaturization ; organ-on-chip ; Pharmacology ; Saúde de qualidade</subject><ispartof>Frontiers in pharmacology, 2023-12, Vol.14, p.1344379-1344379</ispartof><rights>Copyright © 2023 Cruz, Fernandes, Rodrigues, Catarino and Pinho. 2023 Cruz, Fernandes, Rodrigues, Catarino and Pinho</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10749293/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10749293/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38146462$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cruz, Andrea</creatorcontrib><creatorcontrib>Fernandes, Elisabete</creatorcontrib><creatorcontrib>Rodrigues, Raquel Oliveira</creatorcontrib><creatorcontrib>Catarino, Susana Oliveira</creatorcontrib><creatorcontrib>Pinho, Diana</creatorcontrib><title>Editorial: Disease-on-a-chip: from point-of-care to personalized medicine</title><title>Frontiers in pharmacology</title><addtitle>Front Pharmacol</addtitle><description>[Excerpt] Introduction Miniaturization has played a pivotal role in driving innovation in microfluidic devices, particularly in their application across advanced technologies, such as Lab-on-chip platforms, Point-of-care systems, Organ-, Body- and Disease-on-a-chip technology. The personalized nature inherent in these systems, coupled with physiologically relevant readouts, opens novel avenues for individualized disease diagnostics, Figure 1. Additionally, they offer personalized strategies for assessing treatment efficacy and safety. Furthermore, the advancement in micro- and nano-microfluidic fabrication allows parallel analysis of large samples sets and the evaluation of different parameters such as biological molecules, cells or drugs.[...]
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The authors declare financial support: AC and EF are supported by the Lifesaver project funded by the European Union´s Horizon 2020 Research and Innovation Programme under the Grant agreement number 101036702; DP, SC, and RR thanks to Foundation for Science and Technology (FCT) for the contract funding provided through 2021.00027.CEECIND, 2020.00215.CEECIND and 2020.03975.CEECIND, respectively.</description><subject>Biotecnologia Médica</subject><subject>Ciências Médicas</subject><subject>Detection systems</subject><subject>Digital pills</subject><subject>drug-device</subject><subject>lab-on-chip</subject><subject>Microfluidic devices</subject><subject>Miniaturization</subject><subject>organ-on-chip</subject><subject>Pharmacology</subject><subject>Saúde de qualidade</subject><issn>1663-9812</issn><issn>1663-9812</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkU1P3DAQhq2qVUGUP8ChyrGXbP0Vx8OlqigtKyH1Us7WxJ6wRtk4tbNI9Nc3sAsCX2zZ7zye0cPYmeArpSx87acN5pXkUq2E0lq18I4dC2NUDVbI96_OR-y0lDu-LAWgjP7IjpQV2mgjj9n6MsQ55YjDefUjFsJCdRprrP0mTudVn9O2mlIc5zr1tcdM1ZyqiXJJIw7xH4VqSyH6ONIn9qHHodDpYT9hNz8v_1xc1de_f60vvl_XXhkONTUCtGilsp3RqkEOXvOgocFeANimMxSMFrZToiWPFkDwQCpoGRopZKdO2HrPDQnv3JTjFvODSxjd00XKtw7zHP1ATkDb9hRA9wZ1jxZBd9AuLBGAey8W1rc9a9p1yxyexjnj8Ab69mWMG3eb7p3grQYJaiF8ORBy-rujMrttLJ6GAUdKu-IkcCNaq2y7ROU-6nMqJVP_8o_g7tGpe3LqHp26g9Ol6PPrDl9Kng0ugWofyB5xcpnuY5mxOGGldNaaRqn_oeinfg</recordid><startdate>20231211</startdate><enddate>20231211</enddate><creator>Cruz, Andrea</creator><creator>Fernandes, Elisabete</creator><creator>Rodrigues, Raquel Oliveira</creator><creator>Catarino, Susana Oliveira</creator><creator>Pinho, Diana</creator><general>Frontiers Media</general><general>Frontiers Media S.A</general><scope>RCLKO</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20231211</creationdate><title>Editorial: Disease-on-a-chip: from point-of-care to personalized medicine</title><author>Cruz, Andrea ; Fernandes, Elisabete ; Rodrigues, Raquel Oliveira ; Catarino, Susana Oliveira ; Pinho, Diana</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3609-e519417238b6435a09c40d495af19985b6ed6418b317eca89910de3d42d5212b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Biotecnologia Médica</topic><topic>Ciências Médicas</topic><topic>Detection systems</topic><topic>Digital pills</topic><topic>drug-device</topic><topic>lab-on-chip</topic><topic>Microfluidic devices</topic><topic>Miniaturization</topic><topic>organ-on-chip</topic><topic>Pharmacology</topic><topic>Saúde de qualidade</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cruz, Andrea</creatorcontrib><creatorcontrib>Fernandes, Elisabete</creatorcontrib><creatorcontrib>Rodrigues, Raquel Oliveira</creatorcontrib><creatorcontrib>Catarino, Susana Oliveira</creatorcontrib><creatorcontrib>Pinho, Diana</creatorcontrib><collection>RCAAP open access repository</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cruz, Andrea</au><au>Fernandes, Elisabete</au><au>Rodrigues, Raquel Oliveira</au><au>Catarino, Susana Oliveira</au><au>Pinho, Diana</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Editorial: Disease-on-a-chip: from point-of-care to personalized medicine</atitle><jtitle>Frontiers in pharmacology</jtitle><addtitle>Front Pharmacol</addtitle><date>2023-12-11</date><risdate>2023</risdate><volume>14</volume><spage>1344379</spage><epage>1344379</epage><pages>1344379-1344379</pages><issn>1663-9812</issn><eissn>1663-9812</eissn><abstract>[Excerpt] Introduction Miniaturization has played a pivotal role in driving innovation in microfluidic devices, particularly in their application across advanced technologies, such as Lab-on-chip platforms, Point-of-care systems, Organ-, Body- and Disease-on-a-chip technology. The personalized nature inherent in these systems, coupled with physiologically relevant readouts, opens novel avenues for individualized disease diagnostics, Figure 1. Additionally, they offer personalized strategies for assessing treatment efficacy and safety. Furthermore, the advancement in micro- and nano-microfluidic fabrication allows parallel analysis of large samples sets and the evaluation of different parameters such as biological molecules, cells or drugs.[...]
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The authors declare financial support: AC and EF are supported by the Lifesaver project funded by the European Union´s Horizon 2020 Research and Innovation Programme under the Grant agreement number 101036702; DP, SC, and RR thanks to Foundation for Science and Technology (FCT) for the contract funding provided through 2021.00027.CEECIND, 2020.00215.CEECIND and 2020.03975.CEECIND, respectively.</abstract><cop>Switzerland</cop><pub>Frontiers Media</pub><pmid>38146462</pmid><doi>10.3389/fphar.2023.1344379</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1663-9812 |
ispartof | Frontiers in pharmacology, 2023-12, Vol.14, p.1344379-1344379 |
issn | 1663-9812 1663-9812 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_1977fed94f6a4fa8a94b973d41d90cc1 |
source | PubMed Central |
subjects | Biotecnologia Médica Ciências Médicas Detection systems Digital pills drug-device lab-on-chip Microfluidic devices Miniaturization organ-on-chip Pharmacology Saúde de qualidade |
title | Editorial: Disease-on-a-chip: from point-of-care to personalized medicine |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T11%3A11%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Editorial:%20Disease-on-a-chip:%20from%20point-of-care%20to%20personalized%20medicine&rft.jtitle=Frontiers%20in%20pharmacology&rft.au=Cruz,%20Andrea&rft.date=2023-12-11&rft.volume=14&rft.spage=1344379&rft.epage=1344379&rft.pages=1344379-1344379&rft.issn=1663-9812&rft.eissn=1663-9812&rft_id=info:doi/10.3389/fphar.2023.1344379&rft_dat=%3Cproquest_doaj_%3E2906178387%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3609-e519417238b6435a09c40d495af19985b6ed6418b317eca89910de3d42d5212b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2906178387&rft_id=info:pmid/38146462&rfr_iscdi=true |